Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives.

Takashi Morisaki, Kotaro Matsumoto, Hideya Ohnishi, Hideo Kuroki, Eishi Baba, Akira Tasaki, Makoto Kubo, Mitsunari Nakamura, Syoichi Inaba, Koji Yamaguchi, Masao Tanaka, Mitsuo Katano

研究成果: ジャーナルへの寄稿評論記事

50 引用 (Scopus)

抄録

Effective adoptive cancer immunotherapy depends on an ability to generate tumor-antigen-presenting cells and tumor-reactive effector lymphocytes and to deliver these effector cells to the tumor. Dendritic cells (DCs) are the most potent antigen-presenting cells, capable of sensitizing T cells to new and recall antigens. Many studies have shown that tumors express unique proteins that can be loaded on DCs to trigger an immune response. The current experimental and clinical statuses of adoptive transfer of tumor antigen-pulsed DCs and vaccine-primed activated T cells are summarized herein. Clinical trials of antigen-pulsed DCs have been conducted in patients with various types of cancer, including non-Hodgkin lymphoma, multiple myeloma, prostate cancer, renal cell carcinoma, malignant melanoma, colorectal cancer, and non-small cell lung cancer. These studies have shown that antigen-loaded DC vaccination is safe and promising for the treatment of cancer. In addition, tumor vaccine-primed T cells have been shown to induce antitumor activity in vivo. Several clinical studies are being conducted on the use of vaccine-primed T cells such as tumor-drainage lymph node. It is reasonable to consider using both tumor antigen-pulsed DCs and vaccine-primed lymphocytes as adjuvants. We are now investigating the use of autologous whole tumor antigen-pulsed DCs and the DC vaccine-primed activated lymphocytes in patients with multiple metastasis of solid tumors.

元の言語英語
ページ(範囲)175-182
ページ数8
ジャーナルHuman cell : official journal of Human Cell Research Society
16
発行部数4
DOI
出版物ステータス出版済み - 1 1 2003

Fingerprint

Immunotherapy
Dendritic Cells
Vaccines
T-Lymphocytes
Neoplasm Antigens
Neoplasms
Antigen-Presenting Cells
Lymphocytes
Antigens
Adoptive Immunotherapy
Cancer Vaccines
Adoptive Transfer
Multiple Myeloma
Renal Cell Carcinoma
Non-Small Cell Lung Carcinoma
Non-Hodgkin's Lymphoma
Drainage
Colorectal Neoplasms
Melanoma
Prostatic Neoplasms

All Science Journal Classification (ASJC) codes

  • Cell Biology
  • Cancer Research

これを引用

Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients : rationale, current progress, and perspectives. / Morisaki, Takashi; Matsumoto, Kotaro; Ohnishi, Hideya; Kuroki, Hideo; Baba, Eishi; Tasaki, Akira; Kubo, Makoto; Nakamura, Mitsunari; Inaba, Syoichi; Yamaguchi, Koji; Tanaka, Masao; Katano, Mitsuo.

:: Human cell : official journal of Human Cell Research Society, 巻 16, 番号 4, 01.01.2003, p. 175-182.

研究成果: ジャーナルへの寄稿評論記事

Morisaki, Takashi ; Matsumoto, Kotaro ; Ohnishi, Hideya ; Kuroki, Hideo ; Baba, Eishi ; Tasaki, Akira ; Kubo, Makoto ; Nakamura, Mitsunari ; Inaba, Syoichi ; Yamaguchi, Koji ; Tanaka, Masao ; Katano, Mitsuo. / Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients : rationale, current progress, and perspectives. :: Human cell : official journal of Human Cell Research Society. 2003 ; 巻 16, 番号 4. pp. 175-182.
@article{84918887597e4b2d87634ef3973c8f6f,
title = "Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives.",
abstract = "Effective adoptive cancer immunotherapy depends on an ability to generate tumor-antigen-presenting cells and tumor-reactive effector lymphocytes and to deliver these effector cells to the tumor. Dendritic cells (DCs) are the most potent antigen-presenting cells, capable of sensitizing T cells to new and recall antigens. Many studies have shown that tumors express unique proteins that can be loaded on DCs to trigger an immune response. The current experimental and clinical statuses of adoptive transfer of tumor antigen-pulsed DCs and vaccine-primed activated T cells are summarized herein. Clinical trials of antigen-pulsed DCs have been conducted in patients with various types of cancer, including non-Hodgkin lymphoma, multiple myeloma, prostate cancer, renal cell carcinoma, malignant melanoma, colorectal cancer, and non-small cell lung cancer. These studies have shown that antigen-loaded DC vaccination is safe and promising for the treatment of cancer. In addition, tumor vaccine-primed T cells have been shown to induce antitumor activity in vivo. Several clinical studies are being conducted on the use of vaccine-primed T cells such as tumor-drainage lymph node. It is reasonable to consider using both tumor antigen-pulsed DCs and vaccine-primed lymphocytes as adjuvants. We are now investigating the use of autologous whole tumor antigen-pulsed DCs and the DC vaccine-primed activated lymphocytes in patients with multiple metastasis of solid tumors.",
author = "Takashi Morisaki and Kotaro Matsumoto and Hideya Ohnishi and Hideo Kuroki and Eishi Baba and Akira Tasaki and Makoto Kubo and Mitsunari Nakamura and Syoichi Inaba and Koji Yamaguchi and Masao Tanaka and Mitsuo Katano",
year = "2003",
month = "1",
day = "1",
doi = "10.1111/j.1749-0774.2003.tb00151.x",
language = "English",
volume = "16",
pages = "175--182",
journal = "Human Cell",
issn = "0914-7470",
publisher = "Springer Heidelberg",
number = "4",

}

TY - JOUR

T1 - Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients

T2 - rationale, current progress, and perspectives.

AU - Morisaki, Takashi

AU - Matsumoto, Kotaro

AU - Ohnishi, Hideya

AU - Kuroki, Hideo

AU - Baba, Eishi

AU - Tasaki, Akira

AU - Kubo, Makoto

AU - Nakamura, Mitsunari

AU - Inaba, Syoichi

AU - Yamaguchi, Koji

AU - Tanaka, Masao

AU - Katano, Mitsuo

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Effective adoptive cancer immunotherapy depends on an ability to generate tumor-antigen-presenting cells and tumor-reactive effector lymphocytes and to deliver these effector cells to the tumor. Dendritic cells (DCs) are the most potent antigen-presenting cells, capable of sensitizing T cells to new and recall antigens. Many studies have shown that tumors express unique proteins that can be loaded on DCs to trigger an immune response. The current experimental and clinical statuses of adoptive transfer of tumor antigen-pulsed DCs and vaccine-primed activated T cells are summarized herein. Clinical trials of antigen-pulsed DCs have been conducted in patients with various types of cancer, including non-Hodgkin lymphoma, multiple myeloma, prostate cancer, renal cell carcinoma, malignant melanoma, colorectal cancer, and non-small cell lung cancer. These studies have shown that antigen-loaded DC vaccination is safe and promising for the treatment of cancer. In addition, tumor vaccine-primed T cells have been shown to induce antitumor activity in vivo. Several clinical studies are being conducted on the use of vaccine-primed T cells such as tumor-drainage lymph node. It is reasonable to consider using both tumor antigen-pulsed DCs and vaccine-primed lymphocytes as adjuvants. We are now investigating the use of autologous whole tumor antigen-pulsed DCs and the DC vaccine-primed activated lymphocytes in patients with multiple metastasis of solid tumors.

AB - Effective adoptive cancer immunotherapy depends on an ability to generate tumor-antigen-presenting cells and tumor-reactive effector lymphocytes and to deliver these effector cells to the tumor. Dendritic cells (DCs) are the most potent antigen-presenting cells, capable of sensitizing T cells to new and recall antigens. Many studies have shown that tumors express unique proteins that can be loaded on DCs to trigger an immune response. The current experimental and clinical statuses of adoptive transfer of tumor antigen-pulsed DCs and vaccine-primed activated T cells are summarized herein. Clinical trials of antigen-pulsed DCs have been conducted in patients with various types of cancer, including non-Hodgkin lymphoma, multiple myeloma, prostate cancer, renal cell carcinoma, malignant melanoma, colorectal cancer, and non-small cell lung cancer. These studies have shown that antigen-loaded DC vaccination is safe and promising for the treatment of cancer. In addition, tumor vaccine-primed T cells have been shown to induce antitumor activity in vivo. Several clinical studies are being conducted on the use of vaccine-primed T cells such as tumor-drainage lymph node. It is reasonable to consider using both tumor antigen-pulsed DCs and vaccine-primed lymphocytes as adjuvants. We are now investigating the use of autologous whole tumor antigen-pulsed DCs and the DC vaccine-primed activated lymphocytes in patients with multiple metastasis of solid tumors.

UR - http://www.scopus.com/inward/record.url?scp=3042678321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042678321&partnerID=8YFLogxK

U2 - 10.1111/j.1749-0774.2003.tb00151.x

DO - 10.1111/j.1749-0774.2003.tb00151.x

M3 - Review article

C2 - 15147037

AN - SCOPUS:3042678321

VL - 16

SP - 175

EP - 182

JO - Human Cell

JF - Human Cell

SN - 0914-7470

IS - 4

ER -